诺华公司的Fabhalta®在C3型球病患者中显著改善, 计划在年底前获得FDA批准. Novartis's Fabhalta® showed significant improvement in C3 glomerulopathy patients, with plans for FDA approval by year-end.

Novartis宣布了第三阶段APPEAR-C3G研究的可喜成果,表明其口服药物Fabhalta(iptacopan)在一年多的时间里大大减少了C3球状病(C3G)患者的蛋白尿和肾功能的改善。 Novartis announced promising results from the Phase III APPEAR-C3G study, indicating that its oral drug Fabhalta® (iptacopan) significantly reduced proteinuria and improved kidney function in patients with C3 glomerulopathy (C3G) over one year. 这种超罕见肾病目前没有经批准的治疗方法。 This ultra-rare kidney disease currently has no approved treatments. 诺华公司计划在其他地区提交申请后,在年底前申请FDA批准C3G中的Fabhalta. Novartis plans to seek FDA approval for Fabhalta in C3G by year-end, following submissions in other regions.